Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | GABRP | O00591 | 1/20 | 0.59 |
| ▸ | GABRD | O14764 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.59 |
| ▸ | GABRE | P78334 | 1/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.59 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.59 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.59 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285862 | 1.00 | MAPT (0.60) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL24330027 | 0.89 | MAPT (0.49) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL8613887 | 0.86 | GABRP (0.63) | PDK4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14143340 | 0.86 | PDK4 (0.61) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL3226626 | 0.85 | MAPT (0.66) | MAPTLMNAKDM4EALOX15HTR6 | |
| SCHEMBL4773456 | 0.85 | GABRP (0.58) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL6381977 | 0.85 | GABRP (0.56) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL12326386 | 0.85 | GABRP (0.56) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL892861 | 0.85 | GABRP (0.62) | MAPTPDK4GABRPGABRDGABRA1 | |
| SCHEMBL4878519 | 0.85 | TDO2 (0.57) | MAPTPDK4GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022078971-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2022-04-21 | — | — | WO | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| CN-103929961-A | Compounds and therapeutic uses thereof | MYREXIS INC | 2014-07-16 | — | — | CN | disclosed |
| WO-2012177782-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2010097334-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| EP-1777223-A1 | Indole derivatives useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-04-25 | — | — | EP | disclosed |
| WO-2000037074-A1 | MUTILIN 14-ESTER DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-06-29 | — | — | WO | disclosed |
| EP-0619805-B1 | 5-(HETERO- OR CARBOCYCLYLAMINO)-INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1 AGONISTS | PFIZER (US) | 2000-03-15 | — | — | EP | disclosed |
| CN-1045294-C | Indole derivatives | PFIZER (US) | 1999-09-29 | — | — | CN | disclosed |
| WO-1997047302-A1 | INHIBITION OF SEROTONIN REUPTAKE | ELI LILLY AND COMPANY (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5639752-A | SEROTONIN AGONIST | PFIZER INC (US) | 1997-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | MAPT 3977/4885PDK4 439/4885GABRP 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.